|
1
|
Balata H, Fong KM, Hendriks LE, Lam S,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in thoracic oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Urvay SE, Yucel B, Erdis E and Turan N:
Prognostic factors in stage III non-small-cell lung cancer
patients. Asian Pac J Cancer Prev. 17:4693–4697. 2016.PubMed/NCBI
|
|
3
|
Berghmans T, Paesmans M and Sculier JP:
Prognostic factors in stage III non-small cell lung cancer: A
review of conventional, metabolic and new biological variables.
Ther Adv Med Oncol. 3:127–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Center for Chronic Disease
Prevention, Health Promotion (US) Office on Smoking and Health, .
The health consequences of smoking-50 years of progress: A report
of the surgeon general. Centers for Disease Control and Prevention
(US); Atlanta (GA): 2014
|
|
5
|
Rahal Z, El Nemr S, Sinjab A, Chami H,
Tfayli A and Kadara H: Smoking and lung cancer: A geo-regional
perspective. Front Oncol. 7:1942017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tammemägi MC: Selecting lung cancer
screenees using risk prediction models-where do we go from here.
Transl Lung Cancer Res. 7:243–253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(2023), . NCCN Guidelines Version 1.2023 - Non-Small Cell Lung
Cancer, Updates. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfFebruary
1–2023
|
|
8
|
Kumar V, Cohen JT, van Klaveren D,
Soeteman DI, Wong JB, Neumann PJ and Kent DM: Risk-targeted lung
cancer screening: A cost-effectiveness analysis. Ann Intern Med.
168:161–169. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cronin KA, Gail MH, Zou Z, Bach PB,
Virtamo J and Albanes D: Validation of a model of lung cancer risk
prediction among smokers. J Natl Cancer Inst. 98:637–640. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
National Cancer Institute DoCEG, . Lung
cancer risk assessment tool. https://analysistools.cancer.gov/lungCancerRiskAssessment/#/February
2–2023
|
|
11
|
Katki HA, Kovalchik SA, Berg CD, Cheung LC
and Chaturvedi AK: Development and validation of risk models to
select ever-smokers for CT lung cancer screening. JAMA.
315:2300–2311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raji OY, Duffy SW, Agbaje OF, Baker SG,
Christiani DC, Cassidy A and Field JK: Predictive accuracy of the
liverpool lung project risk model for stratifying patients for
computed tomography screening for lung cancer: A case-control and
cohort validation study. Ann Intern Med. 157:242–250. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katki HA, Kovalchik SA, Petito LC, Cheung
LC, Jacobs E, Jemal A, Berg CD and Chaturvedi AK: Implications of
nine risk prediction models for selecting ever-smokers for computed
tomography lung cancer screening. Ann Intern Med. 169:10–19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kauczor HU, Bonomo L, Gaga M, Nackaerts K,
Peled N, Prokop M, Remy-Jardin M, von Stackelberg O and Sculier JP:
ESR/ERS white paper on lung cancer screening. Eur Respir J.
46:28–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gierada DS, Black WC, Chiles C, Pinsky PF
and Yankelevitz DF: Low-dose CT screening for lung cancer: Evidence
from 2 decades of study. Radiol Imaging Cancer. 2:e1900582020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Covington MF, Koppula BR, Fine GC, Salem
AE, Wiggins RH, Hoffman JM and Morton KA: PET-CT in clinical adult
oncology: II. Primary thoracic and breast malignancies. Cancers
(Basel). 14:26892022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gupta RK, Naran S, Lallu S and Fauck R:
The diagnostic value of fine needle aspiration cytology (FNAC) in
the assessment of palpable supraclavicular lymph nodes: A study of
218 cases. Cytopathology. 14:201–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stigt JA, Boers JE and Boomsma MF:
Ultrasound-guided tissue core biopsies in supraclavicular lymph
nodes in patients with suspected thoracic malignancies.
Respiration. 90:412–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muthu V, Sehgal IS, Dhooria S, Prasad KT,
Gupta N, Aggarwal AN and Agarwal R: Endobronchial ultrasound-guided
transbronchial needle aspiration: Techniques and challenges. J
Cytol. 36:65–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng SH and Yang ST: The new 8th TNM
staging system of lung cancer and its potential imaging
interpretation pitfalls and limitations with CT image
demonstrations. Diagn Interv Radiol. 25:270–279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Akata S, Kajiwara N, Park J, Yoshimura M,
Kakizaki D, Abe K, Hirano T, Ohira T, Tsuboi M and Kato H:
Evaluation of chest wall invasion by lung cancer using respiratory
dynamic MRI. J Med Imaging Radiat Oncol. 52:36–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao SJ, Kim AW, Puchalski JT, Bramley K,
Detterbeck FC, Boffa DJ and Decker RH: Indications for invasive
mediastinal staging in patients with early non-small cell lung
cancer staged with PET-CT. Lung Cancer. 109:36–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Flury DV, Minervini F and Kocher GJ:
Heterogeneity of stage IIIA non-small cell lung cancer-different
tumours, different nodal status, different treatment, different
prognosis: A narrative review. Curr Chall ThoracSurg. 4:132020.
View Article : Google Scholar
|
|
27
|
Kutob L and Schneider F: Lung cancer
staging. Surg Pathol Clin. 13:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karkhanis VS and Joshi JM: Pleural
effusion: Diagnosis, treatment, and management. Open Access Emerg
Med. 4:31–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Anevlavis S and Froudarakis ME: Advances
in pleuroscopy. Clin Respir J. 12:839–847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moisiuc FV and Colt HG: Thoracoscopy:
Origins revisited. Respiration. 74:344–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Foucault C, Mordant P, Grand B, Achour K,
Arame A, Dujon A, Barthes FL and Riquet M: Unexpected extensions of
non-small-cell lung cancer diagnosed during surgery: Revisiting
exploratory thoracotomies and incomplete resections. Interact
Cardiovasc Thorac Surg. 16:667–672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rami-Porta R, Call S, Dooms C, Obiols C,
Sánchez M, Travis WD and Vollmer I: Lung cancer staging: A concise
update. Eur Respir J. 51:18001902018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Travis WD, Asamura H, Bankier AA, Beasley
MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D,
Nicholson AG, et al: The IASLC lung cancer staging project:
Proposals for coding T categories for subsolid nodules and
assessment of tumor size in part-solid tumors in the forthcoming
eighth edition of the TNM classification of lung cancer. J Thorac
Oncol. 11:1204–1223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ,
Han J, Choi JY, Kwon OJ, Shim YM and Kim S: Non-small cell lung
cancer: Prospective comparison of integrated FDG PET/CT and CT
alone for preoperative staging. Radiology. 236:1011–1019. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shien K, Toyooka S, Soh J, Okami J,
Higashiyama M, Kadota Y, Maeda H, Hayama M, Chida M, Funaki S, et
al: Clinicopathological characteristics and lymph node metastasis
pathway of non-small-cell lung cancer located in the left lingular
division. Interact Cardiovasc Thorac Surg. 20:791–796. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brierley J.D..Asamura H, van Eycken E and
Rous Brian: TNM Atlas. 7th edition. Wiley-Blackwell; New Jersey,
US: pp. p4482021
|
|
37
|
Van Schil PE, Balduyck B, De Waele M,
Hendriks JM, Hertoghs M and Lauwers P: Surgical treatment of
early-stage non-small-cell lung cancer. EJC suppl. 11:110–122.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Van Schil PE, Rami-Porta R and Asamura H:
The 8th TNM edition for lung cancer: A critical
analysis. Ann Transl Med. 6:872018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brunelli A, Kim AW, Berger KI and
Addrizzo-Harris DJ: Physiologic evaluation of the patient with lung
cancer being considered for resectional surgery: Diagnosis and
management of lung cancer, 3rd ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest.
143:e166S–e190S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee TH, Marcantonio ER, Mangione CM,
Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss
R, Ho KK, et al: Derivation and prospective validation of a simple
index for prediction of cardiac risk of major noncardiac surgery.
Circulation. 100:1043–1049. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saraswat V: Effects of anaesthesia
techniques and drugs on pulmonary function. Indian J Anaesth.
59:557–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ntima NO and Lumb AB: Pulmonary function
tests in anaesthetic practice. BJA Edu. 19:206–211. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Majem M, Hernández-Hernández J,
Hernando-Trancho F, de Dios NR, Sotoca A, Trujillo-Reyes JC,
Vollmer I, Delgado-Bolton R and Provencio M: Multidisciplinary
consensus statement on the clinical management of patients with
stage III non-small cell lung cancer. Clin Transl Oncol. 22:21–36.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Péus D, Newcomb N and Hofer S: Appraisal
of the Karnofsky performance status and proposal of a simple
algorithmic system for its evaluation. BMC Med Inform Decis Mak.
13:722013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chow R, Bruera E, Temel JS, Krishnan M, Im
J and Lock M: Inter-rater reliability in performance status
assessment among healthcare professionals: An updated systematic
review and meta-analysis. Supportive Care Cancer. 28:2071–2078.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Karmakar A, Kumtakar A, Sehgal H, Kumar S
and Kalyanpur A: Interobserver variation in response evaluation
criteria in solid tumors 1.1. Acad Radiol. 26:489–501. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lalchandani UR, Sahai V, Hersberger K,
Francis IR and Wasnik AP: A radiologist's guide to response
evaluation criteria in solid tumors. Curr Probl Diagn Radiol.
48:576–585. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bevans M, Ross A and Cella D:
Patient-reported outcomes measurement information system (PROMIS):
Efficient, standardized tools to measure self-reported health and
quality of life. Nurs Outlook. 62:339–345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kunitoh H and Suzuki K: How to evaluate
the risk/benefit of trimodality therapy in locally advanced
non-small-cell lung cancer. Br J Cancer. 96:1498–1503. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rusch VW, Giroux DJ, Kraut MJ, Crowley J,
Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes
R, et al: Induction chemoradiation and surgical resection for
non-small cell lung carcinomas of the superior sulcus: Initial
results of Southwest oncology group trial 9416 (Intergroup Trial
0160). J Thoracic Cardiovasc Surg. 121:472–483. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rivas-Perez H and Nana-Sinkam P:
Integrating pulmonary rehabilitation into the multidisciplinary
management of lung cancer: A review. Respir Med. 109:437–442. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cortes AA, Urquizu LC and Cubero JH:
Adjuvant chemotherapy in non-small cell lung cancer:
State-of-the-art. Transl Lung Cancer Res. 4:191–197.
2015.PubMed/NCBI
|
|
56
|
Pennell NA, Neal JW, Chaft JE, Azzoli CG,
Janne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, et
al: SELECT: A phase II trial of adjuvant erlotinib in patients with
resected epidermal growth factor receptor-mutant non-small-cell
lung cancer. J Clin Oncol. 37:97–104. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
U.S. Food and drug administration (FDA), .
FDA approves osimertinib as adjuvant therapy for non-small cell
lung cancer with EGFR mutations. FDA. 2020.
|
|
58
|
Furuse K, Fukuoka M, Kawahara M, Nishikawa
H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of
concurrent versus sequential thoracic radiotherapy in combination
with mitomycin, vindesine, and cisplatin in unresectable stage III
non-small-cell lung cancer. J Clin Oncol. 17:2692–2699. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jeremic B, Shibamoto Y, Acimovic L and
Milisavljevic S: Hyperfractionated radiation therapy with or
without concurrent low-dose daily carboplatin/etoposide for stage
III non-small-cell lung cancer: A randomized study. J Clin Oncol.
14:1065–1070. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Strøm HH, Bremnes RM, Sundstrøm SH,
Helbekkmo N and Aasebø U: Poor prognosis patients with inoperable
locally advanced NSCLC and large tumors benefit from palliative
chemoradiotherapy: A subset analysis from a randomized clinical
phase III trial. J Thorac Oncol. 9:825–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hung MS, Wu YF and Chen YC: Efficacy of
chemoradiotherapy versus radiation alone in patients with
inoperable locally advanced non-small-cell lung cancer: A
meta-analysis and systematic review. Medicine (Baltimore).
98:e161672019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Auperin A, Le Pechoux C, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, et al: Meta-analysis of concomitant versus sequential
radiochemotherapy in locally advanced non-small-cell lung cancer. J
Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
U.S. Food and drug administration (FDA), .
FDA expands pembrolizumab indication for first-line treatment of
NSCLC (TPS ≥1%). FDA. 2019.
|
|
64
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Botticella A, Mezquita L, Le Pechoux C and
Planchard D: Durvalumab for stage III non-small-cell lung cancer
patients: Clinical evidence and real-world experience. Ther Adv
Respir Dis. 13:17534666198855302019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lee JG, Lee CY, Park IK, Kim DJ, Cho SH,
Kim KD and Chung KY: The prognostic significance of multiple
station N2 in patients with surgically resected stage IIIA N2
non-small cell lung cancer. J Korean Med Sci. 23:604–608. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Quint LE: Lung cancer: Assessing
resectability. Cancer Imaging. 4:15–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Biancosino C, Krüger M, Vollmer E and
Welker L: Intraoperative fine needle aspirations-diagnosis and
typing of lung cancer in small biopsies: Challenges and
limitations. Diagn Pathol. 11:592016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu T, Chen Z, Dang J and Li G: The role
of surgery in stage I to III small cell lung cancer: A systematic
review and meta-analysis. PLoS One. 13:e02100012018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Suzuki S and Goto T: Role of surgical
intervention in unresectable non-small cell lung cancer. J Clin
Med. 9:38812020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jeremic B, Casas F, Dubinsky P,
Gomez-Caamano A, Cihoric N, Videtic G and Latinovic M: Combined
modality therapy in stage IIIA non-small cell lung cancer: Clarity
or confusion despite the highest level of evidence? J Radiat Res.
58:267–272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dehing-Oberije C, De Ruysscher D, van
Baardwijk A, Yu S, Rao B and Lambin P: The importance of patient
characteristics for the prediction of radiation-induced lung
toxicity. Radiother Oncol. 91:421–426. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang W, Xu Y, Schipper M, Matuszak MM,
Ritter T, Cao Y, Haken RK and Kong FM: Effect of normal lung
definition on lung dosimetry and lung toxicity prediction in
radiation therapy treatment planning. Int J Radiat Oncol Biol Phys.
86:956–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
De Ruysscher D, Faivre-Finn C, Moeller D,
Nestle U, Hurkmans CW, Le Péchoux C, Belderbos J, Guckenberger M
and Senan S: European organization for research and treatment of
cancer (EORTC) recommendations for planning and delivery of
high-dose, high precision radiotherapy for lung cancer. Radiother
Oncol. 124:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Keall PJ, Mageras GS, Balter JM, Emery RS,
Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, et
al: The management of respiratory motion in radiation oncology
report of AAPM task group 76. Med Phys. 33:3874–3900. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Naito Y, Kubota K, Nihei K, Fujii T, Yoh
K, Niho S, Goto K, Ohmatsu H, Saijo N and Nishiwaki Y: Concurrent
chemoradiotherapy with cisplatin and vinorelbine for stage III
non-small cell lung cancer. J Thorac Oncol. 3:617–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L,
Shi A, Jiang W, Xu Y, Zhou Z, et al: Etoposide and cisplatin versus
paclitaxel and carboplatin with concurrent thoracic radiotherapy in
unresectable stage III non-small cell lung cancer: A multicenter
randomized phase III trial. Ann Oncol. 28:777–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Rami–Porta R, Wittekind C and Goldstraw P;
International Association for the Study of Lung Cancer (IASLC)
Staging Committee, : Complete resection in lung cancer surgery:
Proposed definition. Lung Cancer. 49:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sonobe M, Yutaka Y, Nakajima D, Hamaji M,
Menju T, Ohsumi A, Chen-Yoshikawa TF, Sato T and Date H: Salvage
surgery after chemotherapy or chemoradiotherapy for initially
unresectable lung carcinoma. Ann Thorac Surg. 108:1664–1670. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Xu XL, Dan L, Chen W, Zhu SM and Mao WM:
Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery
is superior to that followed by definitive chemoradiation or
radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: A
meta-analysis and system review. Onco Targets Ther. 9:845–853.
2016.PubMed/NCBI
|
|
82
|
Lardinois D, Schallberger A, Betticher D
and Ris HB: Postinduction video-mediastinoscopy is as accurate and
safe as video-mediastinoscopy in patients without pretreatment for
potentially operable non-small cell lung cancer. Ann Thorac Surg.
75:1102–1106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Castello A, Rossi S and Lopci E: 18F-FDG
PET/CT in restaging and evaluation of response to therapy in lung
cancer: State of the art. Curr Radiopharm. 13:228–237. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Dane B, Grechushkin V, Plank A, Moore W
and Bilfinger T: PET/CT vs. non-contrast CT alone for surveillance
1-year post lobectomy for stage I non-small-cell lung cancer. Am J
Nucl Med Mol Imaging. 3:408–416. 2013.PubMed/NCBI
|
|
85
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
